These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8496530)

  • 1. Predictors of defibrillation efficacy in patients undergoing epicardial defibrillator implantation. The Multicenter Pacemaker-Cardioverter-Defibrillator (PCD) Investigators Group.
    Leitch JW; Yee R
    J Am Coll Cardiol; 1993 Jun; 21(7):1632-7. PubMed ID: 8496530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial clinical experience with endocardial defibrillation using an implantable cardioverter/defibrillator with a triple-electrode system.
    Saksena S; Tullo NG; Krol RB; Mauro AM
    Arch Intern Med; 1989 Oct; 149(10):2333-9. PubMed ID: 2802898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upper limit of vulnerability is a good estimator of shock strength associated with 90% probability of successful defibrillation in humans with transvenous implantable cardioverter-defibrillators.
    Swerdlow CD; Ahern T; Kass RM; Davie S; Mandel WJ; Chen PS
    J Am Coll Cardiol; 1996 Apr; 27(5):1112-8. PubMed ID: 8609329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defibrillation thresholds and perioperative mortality associated with endocardial and epicardial defibrillation lead systems. The PCD investigators and participating institutions.
    Saksena S
    Pacing Clin Electrophysiol; 1993 Jan; 16(1 Pt 2):202-7. PubMed ID: 7681572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active Can Investigators.
    Bardy GH; Yee R; Jung W
    J Am Coll Cardiol; 1996 Aug; 28(2):400-10. PubMed ID: 8800117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination biphasic waveform plus sequential pulse defibrillation improves defibrillation efficacy of a nonthoracotomy lead system.
    Exner D; Yee R; Jones DL; Klein GJ; Mehra R
    J Am Coll Cardiol; 1994 Feb; 23(2):317-22. PubMed ID: 8294680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful implantation of cardioverter-defibrillator systems in patients with elevated defibrillation thresholds.
    Brooks R; Torchiana D; Vlahakes GJ; Ruskin JN; McGovern BA; Garan H
    J Am Coll Cardiol; 1993 Aug; 22(2):569-74. PubMed ID: 8335831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Implantable cardioverter/defibrillator: long-term stability of the defibrillation threshold with a unipolar electrode configuration (active-can")].
    Knuefermann P; Wolpert C; Spehl S; Korte T; Manz M; Lüderitz B; Jung W
    Z Kardiol; 2000 Sep; 89(9):774-80. PubMed ID: 11077687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Truncated biphasic pulses for transthoracic defibrillation.
    Bardy GH; Gliner BE; Kudenchuk PJ; Poole JE; Dolack GL; Jones GK; Anderson J; Troutman C; Johnson G
    Circulation; 1995 Mar; 91(6):1768-74. PubMed ID: 7882486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of antiarrhythmic drugs on epicardial defibrillation energy requirements and the rate of defibrillator discharges.
    Jung W; Manz M; Pfeiffer D; Tebbenjohanns J; Pizzulli L; Lüderitz B
    Pacing Clin Electrophysiol; 1993 Jan; 16(1 Pt 2):198-201. PubMed ID: 7681571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of epicardial patches on defibrillation threshold with nonthoracotomy lead configurations.
    Fotuhi PC; Ideker RE; Idriss SF; Callihan RL; Walker RG; Alt EU
    Circulation; 1995 Nov; 92(10):3082-8. PubMed ID: 7586279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of implantable defibrillator therapy with programmed shock energy at twice the augmented step-down defibrillation threshold: results of the prospective, randomized, multicenter Low-Energy Endotak Trial.
    Neuzner J; Liebrich A; Jung J; Himmrich E; Pitschner HF; Winter J; Vester EG; Michel U; Nisam S; Heisel A
    Am J Cardiol; 1999 Mar; 83(5B):34D-39D. PubMed ID: 10089837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ventricular fibrillation duration on the defibrillation threshold in humans.
    Gradaus R; Bode-Schnurbus L; Weber M; Rötker J; Hammel D; Breithardt G; Böcker D
    Pacing Clin Electrophysiol; 2002 Jan; 25(1):14-9. PubMed ID: 11877930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoracotomy: an international multicenter study. PCD Investigator Group.
    J Am Coll Cardiol; 1994 Jun; 23(7):1521-30. PubMed ID: 8195508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Suchalla R; Mermi J; Dörnberger V; Seipel L
    Int J Cardiol; 1999 Jun; 69(3):271-9. PubMed ID: 10402110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of defibrillation efficacy using implantable cardioverter-defibrillator with single- or dual-coil defibrillation leads and active can.
    Lubiński A; Lewicka-Nowak E; Zienciuk A; Królak T; Kempa M; Pazdyga A; Raczak G; Swiatecka G
    Kardiol Pol; 2005 Sep; 63(3):234-41; discussion 242-3. PubMed ID: 16180177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants.
    Fromer M; Brachmann J; Block M; Siebels J; Hoffmann E; Almendral J; Ohm OJ; den Dulk K; Coumel P; Camm AJ
    Circulation; 1992 Aug; 86(2):363-74. PubMed ID: 1638705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reproducibility of the effectiveness of defibrillation for terminating induced ventricular fibrillation using intraoperatively measured defibrillation threshold energy in patients with implanted cardioverter-defibrillator].
    Jung J; Neuzner J; Himmrich E; Vester E; Michel U; Fries R; Pitschner H; Liebrich A; Ganschow U; Heisel A
    Z Kardiol; 1998 Dec; 87(12):971-7. PubMed ID: 10025070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term multicenter experience with a second-generation implantable pacemaker-defibrillator in patients with malignant ventricular tachyarrhythmias. The Guardian Multicenter Investigators Group.
    Saksena S; Poczobutt-Johanos M; Castle LW; Fogoros RN; Alpert BL; Kron J; Pacifico A; Griffin J; Ruskin JN; Kehoe RF
    J Am Coll Cardiol; 1992 Mar; 19(3):490-9. PubMed ID: 1537999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.